Literature DB >> 11313426

Kinetics of TCR use in response to repeated epitope-specific immunization.

V Monsurrò1, M B Nielsen, A Perez-Diez, M E Dudley, E Wang, S A Rosenberg, F M Marincola.   

Abstract

Selection of T cell-directed immunization strategies is based extensively on discordant information derived from preclinical models. We characterized the kinetics of T cell selection in response to repeated antigenic challenge. By enumerating with epitope/HLA tetrameric complexes (tHLA) vaccine-elicited T cell precursor frequencies (Tc-pf) in melanoma patients exposed to the modified gp100 epitope gp100:209-217 (g209-2M) we observed in most patients that the Tc-pf increased with number of immunizations. One patient's kinetics were further characterized. Dissociation kinetics of g209-2M/tHLA suggested enrichment of T cell effector populations expressing TCR with progressively higher affinity. Furthermore, vaccine-elicited T cells maintained the ability to express IFN-gamma ex vivo and proliferate in vitro. Thus, repeated exposure to immunogenic peptides benefited immune competence. These results provide a rationale for immunization strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313426     DOI: 10.4049/jimmunol.166.9.5817

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Functional heterogeneity of vaccine-induced CD8(+) T cells.

Authors:  Vladia Monsurrò; Dirk Nagorsen; Ena Wang; Maurizio Provenzano; Mark E Dudley; Steven A Rosenberg; Francesco M Marincola
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.

Authors:  Miles P Davenport; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  Intensity of the vaccine-elicited immune response determines tumor clearance.

Authors:  Ainhoa Perez-Diez; Paul J Spiess; Nicholas P Restifo; Polly Matzinger; Francesco M Marincola
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

Review 4.  Understanding the response to immunotherapy in humans.

Authors:  Ena Wang; Monica C Panelli; Francesco M Marincola
Journal:  Springer Semin Immunopathol       Date:  2005-01-22

5.  Novel design architecture for genetic stability of recombinant poliovirus: the manipulation of G/C contents and their distribution patterns increases the genetic stability of inserts in a poliovirus-based RPS-Vax vector system.

Authors:  Sang-Gu Lee; Dae-You Kim; Byung-Hwa Hyun; Yong-Soo Bae
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

6.  Analysis of vaccine-induced T cells in humans with cancer.

Authors:  Stefanie L Slezak; Andrea Worschech; Ena Wang; David F Stroncek; Francesco M Marincola
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

7.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Authors:  Daniel E Speiser; Danielle Liénard; Nathalie Rufer; Verena Rubio-Godoy; Donata Rimoldi; Ferdy Lejeune; Arthur M Krieg; Jean-Charles Cerottini; Pedro Romero
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

8.  Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.

Authors:  D Nagorsen; M Panelli; M E Dudley; S E Finkelstein; S A Rosenberg; F M Marincola
Journal:  Gene Ther       Date:  2003-09       Impact factor: 5.250

9.  MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.

Authors:  P Mukherjee; A R Ginardi; C S Madsen; T L Tinder; F Jacobs; J Parker; B Agrawal; B M Longenecker; S J Gendler
Journal:  Glycoconj J       Date:  2001 Nov-Dec       Impact factor: 2.916

Review 10.  Overview of melanoma vaccines and promising approaches.

Authors:  Monica C Panelli; Ena Wang; Vladia Monsurrò; Ping Jin; Katia Zavaglia; Kina Smith; Yvonne Ngalame; Francesco M Marincola
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.